A randomized placebo controlled double blind study of danazol in hemophilia A

J. Mehta*, S. Singhal, M. V. Kamath, B. C. Mehta

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

A randomized double-blind placebo-controlled crossover trial of danazol was carried out in 19 cases of hemophilia A. Danazol was given for 3 months at a dose of 150 mg/day to patients under 15 years of age, and 300 mg/day to older patients. The basal factor VIII:C level was 8.3 ± 5.6% (mean ± SD), and after 3 months of danazol treatment was 15.3 ± 11.0% (p = 0.02). Six patients (basal factor VIII:C 2-22%) showed a 1.36- to 2.87-fold elevation of factor VIII:C levels after danazol. 0/2, 1/4 and 5/13 cases of severe, moderate and mild disease, respectively, responded. Decreases in the number of bleeding episodes and cryoprecipitate requirement were seen in the responders. No adverse reactions to danazol were encountered. Danazol appears to raise the factor VIII:C levels in selected cases of hemophilia A.

Original languageEnglish (US)
Pages (from-to)14-16
Number of pages3
JournalActa Haematologica
Volume88
Issue number1
DOIs
StatePublished - Jan 1 1992

Keywords

  • Danazol
  • Factor VIII:C
  • Hemophilia A

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A randomized placebo controlled double blind study of danazol in hemophilia A'. Together they form a unique fingerprint.

Cite this